AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19750065
Drug: Computerized Decision
RxNorm normalized name: Precise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized Decision Support System (CDSS) for MDD treatment
Trial: 19750065
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care for MDD treatment
Trial: 19751237
Drug: Rituximab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (4 weekly doses)
Trial: 19752530
Drug: Elevated uric
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated uric acid group (>6 mg/dl)
Trial: 19752530
Drug: Normal uric
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal uric acid group (≤6 mg/dl)
Trial: 19753491
Drug: Trypanocidal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trypanocidal treatment with benznidazole
Trial: 19753491
Drug: Antitrypanosomal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antitrypanosomal therapy with benznidazole
Trial: 19755203
Drug: hsCRP≥6.5 mg/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP≥6.5 mg/L
Trial: 19755203
Drug: NTpro-BNP≥4302 pg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTpro-BNP≥4302 pg/mL
Trial: 19755203
Drug: Na serum
RxNorm normalized name: GLYCERIN 10.82 g in 100 mL TOPICAL LIQUID [Bio DNA Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na serum level≤135 mEq/L
Trial: 19755203
Drug: Sodium plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium plasma levels ≤135 mEq/L
Trial: 19755203
Drug: Sodium plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium plasma levels ≤135 mEq/L + NTpro-BNP≥4302 pg/mL
Trial: 19757984
Drug: Post-bronchodilator FEV(1)/FVC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-bronchodilator FEV(1)/FVC ratio < or = 0.70
Trial: 19757984
Drug: Post-bronchodilator FEV(1)/FVC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-bronchodilator FEV(1)/FVC ratio > 0.70
Trial: 19758095
Drug: Safe water
RxNorm normalized name: Safe-Guard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safe water storage vessels, hygiene education, and bleach for household water treatment (Cohort B)
Trial: 19770418
Drug: Surgery and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery and perioperative INGN 201 gene therapy
Trial: 19771508
Drug: Epirubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin and docetaxel (2 or 3 weekly intervals)
Trial: 19771508
Drug: Post-treatment tumor
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment tumor cellularity
Trial: 19773266
Drug: CD20 positivity
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD20 positivity over 20% in patients with WBC over 30x10(9)/L
Trial: 19782361
Drug: Atorvastatin 10mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10mg per day for one year
Trial: 19786468
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (enoxaparin or nadroparin)
Trial: 19786468
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of heparin therapy longer than 9 days
Trial: 19786617
Drug: (131)I-BC8 antibody
RxNorm normalized name: Anti-b1 antibody I-131
DrugBank: Tositumomab I-131 (DB17991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (131)I-BC8 antibody (Ab; BC8) plus fludarabine and 2 Gy total body irradiation
Trial: 19786667
Drug: Lenalidomide 15
RxNorm normalized name: lenalidomide 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 15 mg/d plus bortezomib 1.0 mg/m(2)
Trial: 19786927
Drug: Lotrafilcon A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrafilcon A lenses for monthly continuous wear (CW)
Trial: 19788755
Drug: Community care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community care coordinators (CCCs) providing care every three months in clinics and monthly in the community; CCCs underwent intensive training and mentoring.
Trial: 19788755
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care with monthly clinic visits.
Trial: 19789316
Drug: SGN-30 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGN-30 (4 mg/kg to 12 mg/kg, i.v. every 3 weeks for six doses, with potential for two additional courses)
Trial: 19796996
Drug: Transoral endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transoral endoscopic restrictive implant system
Trial: 19799842
Drug: S. aureus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. aureus conjugate vaccine (StaphVAX) comprised of capsular polysaccharides 5 and 8 (CP5, CP8)
Trial: 19799842
Drug: S. aureus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. aureus conjugate vaccine (StaphVAX)
Trial: 19805455
Drug: rHuPH20-facilitated subcutaneous
RxNorm normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuPH20-facilitated subcutaneous rehydration
Trial: 19806596
Drug: Sorafenib as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib as adjuvant treatment
Trial: 19809305
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of XIIaA and BNP
Trial: 19811637
Drug: AS1402 (1-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS1402 (1-16 mg/kg) administered via intravenous infusion every 1 to 3 weeks until disease progression.
Trial: 19811637
Drug: AS1402 (1-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS1402 (1-16 mg/kg) administered via intravenous infusion.
Trial: 19812383
Drug: Busulfan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation
Trial: 19812461
Drug: Memantine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine at a target dose of 20 mg daily for 26 weeks
Trial: 19817748
Drug: Vorinostat 100
RxNorm normalized name: vorinostat 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat 100 or 200 mg administered twice daily for 14 consecutive days followed by a 1-week rest interval.
Trial: 19817748
Drug: Vorinostat 200
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat 200 mg
Trial: 19818257
Drug: High-dose ziprasidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ziprasidone
Trial: 19820552
Drug: Escitalopram (ESC)
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram (ESC) plus bupropion (BUP), rapid dose escalation to ESC 40 mg/day plus BUP 400 to 450 mg/day by study day 15
Trial: 19829297
Drug: Enoxaparin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (1 mg/kg +/-20% s.c. b.i.d.)
Trial: 19833304
Drug: Adenosine administered
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine administered by intravenous infusion (140 microg/kg/min) to obtain hyperemic flow profiles.
Trial: 19835828
Drug: AS03(A)-adjuvanted A/Indonesia/5/2005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A)-adjuvanted A/Indonesia/5/2005 vaccine (single booster dose)
Trial: 19835828
Drug: AS03(A)-adjuvanted A/Vietnam/1194/2004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A)-adjuvanted A/Vietnam/1194/2004 vaccine (primed 14 months earlier)
Trial: 19835828
Drug: Non-adjuvanted A/Vietnam/1194/2004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted A/Vietnam/1194/2004 vaccine (primed 14 months earlier, two booster doses)
Trial: 19835828
Drug: Un-primed control
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Un-primed control group (two doses of adjuvanted vaccine)
Trial: 19837930
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion at 0.25 pmol x kg(-1) x min(-1) on day 1 and day 3
Trial: 19837930
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion on day 1 and day 3
Trial: 19837930
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion in healthy controls on day 1
Trial: 19838774
Drug: Rituximab therapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab therapy with co-treatment
Trial: 19843887
Drug: Lumiliximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiliximab (375 mg/m² or 500 mg/m²) combined with fludarabine, cyclophosphamide, and rituximab (FCR) for 6 cycles
Trial: 19843899
Drug: Omega-3 acid
RxNorm normalized name: OMEGA-3 ACID
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 acid ethyl esters (2 g/d, containing 930 mg EPA and 750 mg DHA)
Trial: 19843899
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil placebo capsules
Trial: 19846066
Drug: TA-CD vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-CD vaccine (82 microg, n = 4; 360 microg, n = 6) administered at weeks 1, 3, 5, and 9
Trial: 19846066
Drug: Cocaine (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (0 mg, 25 mg, 50 mg)
Trial: 19846730
Drug: LA volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA volume index >32 mL/m(2)
Trial: 19850694
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone withdrawal (L-T4)
Trial: 19852963
Drug: Des-gamma-carboxy prothrombin
RxNorm normalized name: Des-gamma-carboxy prothrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Des-gamma-carboxy prothrombin (DCP) at month 0 with cutoff of 40 mAU/mL
Trial: 19852963
Drug: Des-gamma-carboxy prothrombin
RxNorm normalized name: Des-gamma-carboxy prothrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Des-gamma-carboxy prothrombin (DCP) at month 0 with cutoff of 150 mAU/mL
Trial: 19852963
Drug: Alpha-fetoprotein (AFP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-fetoprotein (AFP) at month 0 with cutoff of 20 ng/mL
Trial: 19852963
Drug: Alpha-fetoprotein (AFP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-fetoprotein (AFP) at month 0 with cutoff of 200 ng/mL
Trial: 19852963
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of DCP and AFP
Trial: 19852963
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tests
Trial: 19854499
Drug: AAV2-hRPE65v2 gene
RxNorm normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV2-hRPE65v2 gene therapy (1.5 x 10(10) vector genomes, 4.8 x 10(10) vector genomes, 1.5 x 10(11) vector genomes)
Trial: 19854499
Drug: AAV2-hRPE65v2 gene
RxNorm normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV2-hRPE65v2 gene therapy
Trial: 19856395
Drug: Study medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medication adherence (MedAd)
Trial: 19856395
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence during dose titration
Trial: 19858149
Drug: Maternal circulating
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal circulating blood group antibodies
Trial: 19858174
Drug: Nutritious, culturally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritious, culturally appropriate daily meal (weeks 1-8) and food package (weeks 9-32) (n=137)
Trial: 19858725
Drug: hs-CRP >or=2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP >or=2 mg/l in patients without prior CVD and LDL <3.4 mmol/l
Trial: 19864401
Drug: Dietary intake
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intake of fish (1-2 servings, 25-50 g/week)
Trial: 19864401
Drug: <101 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <101 g fish/week
Trial: 19864401
Drug: >=101 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >=101 g fish/week
Trial: 19877976
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Fluoxetine and Cognitive-Behavioral Therapy (COMB)
Trial: 19877976
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FLX) or Cognitive-Behavioral Therapy (CBT)
Trial: 19882497
Drug: Oral corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroid use
Trial: 19886987
Drug: Protracted 5FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protracted 5FU intravenous infusion (200 mg/m2 daily) plus LAR octreotide (20 mg monthly)
Trial: 19888782
Drug: Triptorelin embonate
RxNorm normalized name: Triptorelin embonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin embonate (pamoate) 22.5 mg, two consecutive intramuscular injections at an interval of 24 weeks
Trial: 19889129
Drug: Galantamine-ER 8-24
RxNorm normalized name: Galantamine Extended-Release Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine-ER 8-24 mg/day for 4 months
Trial: 19889129
Drug: Galantamine-ER treatment
RxNorm normalized name: galantamine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine-ER treatment
Trial: 19889819
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg phytosterols/d
Trial: 19889819
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg phytosterols/d
Trial: 19889819
Drug: 59 mg
RxNorm normalized name: aspirin 259 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 59 mg phytosterols/d (control)
Trial: 19889819
Drug: 459 mg
RxNorm normalized name: petrolatum 459 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 459 mg phytosterols/d
Trial: 19890127
Drug: Synthetic peptide-based
RxNorm normalized name: Copolymer I (synthetic peptide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic peptide-based erythropoietin-receptor agonist (Hematide); administered subcutaneously at an initial dose of 0.05 mg/kg every 4 weeks
Trial: 19890203
Drug: Lopinavir 400
RxNorm normalized name: LOPINAVIR 400MG/RITONAVIR 100MG/5ML SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir 400 mg and Ritonavir 100 mg, given twice daily for 4 weeks
Trial: 19897179
Drug: Repeated-dose intravenous
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated-dose intravenous ketamine (six infusions over 12 days)
Trial: 19901191
Drug: Reconstituted high-density
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted high-density lipoprotein (rHDL) infusion (CSL-111; 20 mg . kg(-1) . h(-1)) for 4 hours
Trial: 19902266
Drug: Ibuprofen treatment
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen treatment for patent ductus arteriosus (PDA)
Trial: 19902266
Drug: No ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: No ibuprofen treatment
Trial: 19902266
Drug: Ibuprofen treatment
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen treatment for PDA
Trial: 19906082
Drug: Single intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravitreal injection of triamcinolone combined with bevacizumab
Trial: 19906624
Drug: Tenofovir and
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir and emtricitabine once daily plus nevirapine twice daily
Trial: 19909496
Drug: Progressive high-impact
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive high-impact training (high intensity levels > 3.9 g)
Trial: 19909496
Drug: Progressive high-impact
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive high-impact training (first three months of exercise exceeding 1.1 g)
Trial: 19915292
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day of etidronate cyclically
Trial: 19915292
Drug: High-dose glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glucocorticoids (GCs)
Trial: 19916705
Drug: BIAsp 30
RxNorm normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BIAsp 30 (treatment-naïve subgroup)
Trial: 19916705
Drug: BIAsp 30
RxNorm normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BIAsp 30 (insulin +/- OADs subgroup)
Trial: 19918104
Drug: Generic lopinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic lopinavir/ritonavir 200/50 mg tablet formulation (400/100 mg twice daily)
Trial: 19918104
Drug: Kaletra(R) soft-gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaletra(R) soft-gel capsules
Trial: 19918104
Drug: Generic lopinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic lopinavir/ritonavir tablet
Trial: 25758746
Drug: Dasatinib 100
RxNorm normalized name: dasatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 100 mg twice daily
Trial: 19920819
Drug: Bevacizumab with
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab with metronomic etoposide (10 mg kg(-1) bevacizumab biweekly and 50 mg m(-2) etoposide daily for 21 consecutive days each month)
Trial: 19923375
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg folate/d
Trial: 19923475
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with isoniazid, gatifloxicin, levofloxacin, and moxifloxacin
Trial: 19929182
Drug: Prescription redemption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription redemption for ACE inhibitor or angiotensin-II receptor antagonist
Trial: 19930156
Drug: VEGFR2-169 peptide
RxNorm normalized name: Vegfr2-169 peptide vaccine
DrugBank: VEGFR2-169 (DB16152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGFR2-169 peptide vaccine combined with gemcitabine (1000 mg/m² on days 1, 8, and 15 in a 28-day cycle)
Trial: 19930156
Drug: VEGFR2-169 peptide
RxNorm normalized name: Vegfr2-169 peptide vaccine
DrugBank: VEGFR2-169 (DB16152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGFR2-169 peptide vaccine combined with gemcitabine
Trial: 19930156
Drug: VEGFR2-169 peptide
RxNorm normalized name: Vegfr2-169 peptide vaccine
DrugBank: VEGFR2-169 (DB16152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGFR2-169 peptide vaccine
Trial: 19930599
Drug: Nedaplatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedaplatin (10 mg/body/day) and 5-FU (500 mg/body/day) with radiation (50.4-66 Gy)
Trial: 19931137
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m² IV and oxaliplatin 130 mg/m² IV every 21 days
Trial: 19932054
Drug: GEMOX-B (bevacizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEMOX-B (bevacizumab 10 mg/kg, gemcitabine 1000 mg/m(2), oxaliplatin 85 mg/m(2))
Trial: 19932729
Drug: 14.6 g
RxNorm normalized name: ZINC OXIDE 14.6 g in 100 g TOPICAL CREAM [Practical Alchemy Hydrating SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14.6 g cis-9,trans-11 CLA and 4.7 g trans-10,cis-12 CLA isomers daily for 3 weeks
Trial: 19933994
Drug: Metformin (1,700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,700 mg daily) plus folic acid (400 microg daily), n = 25
Trial: 19936297
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% permethrin for scabies treatment and referral for pyoderma treatment according to guidelines.
Trial: 19936297
Drug: Annual mass
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual mass scabies treatment with 5% permethrin cream offered to all community residents.
Trial: 19946413
Drug: Vandetanib 100
RxNorm normalized name: vandetanib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 100 mg/day